BLR-200 / BLR Bio - LARVOL DELTA

Rosalind Franklin University Incubator Company Announces Positive Anti-Fibrotic Effects in Lung Fibrosis Model (PRNewswire) - "BLR Bio...announced new data on its novel therapy for systemic sclerosis and lung fibrosis at the British Society for Rheumatology (BSR) Annual Conference this week in Manchester, UK....In the new study, presented by Dr. Andrew Leask at the University of Saskatchewan in Canada, BLR 200, the company's lead compound, demonstrated the ability to reduce key disease tissue markers for fibrotic lung disease. Reductions were shown in Ashcroft scores, collagen levels, and both fibronectin-1 (FN-1) and profibrotic CCN4, signaling molecules involved in the development of scar tissue. Dr. Leask is a leading expert in fibrosis and CCN proteins and a long-term collaborator with BLR Bio."

Preclinical • Fibrosis • Immunology • Systemic Sclerosis

Rosalind Franklin University Helix 51 Incubator Company Granted FDA Orphan Drug Designation for Treatment of Scleroderma (PRNewswire) - "BLR Bio...announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma....BLR-200 is different from other therapies now in development for the treatment of systemic sclerosis."

Orphan drug • Immunology • Scleroderma • Systemic Sclerosis